Skip to content

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00675077
Enrollment
5
Registered
2008-05-08
Start date
2008-05-31
Completion date
2010-06-30
Last updated
2009-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease

Keywords

Akinetic-Rigid Variant of Huntington Disease, Chorea, Chronic Progressive Hereditary (Huntington), Chronic Progressive Hereditary Chorea (Huntington), Huntington Chorea, Huntington Chronic Progressive Hereditary Chorea, Huntington Disease, Akinetic-Rigid Variant, Huntington Disease, Juvenile, Huntington Disease, Juvenile-Onset

Brief summary

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances. This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Detailed description

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.

Interventions

Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Sponsors

GAAD Medical Research Institute Inc.
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* People with HD

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Treatment of people with HD2 years

Secondary

MeasureTime frame
Rehabilitation of people with HD2 Years

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026